

Marcus Axelsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8156052/publications.pdf>

Version: 2024-02-01

44
papers

2,653
citations

331538
21
h-index

254106
43
g-index

47
all docs

47
docs citations

47
times ranked

3782
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 872-884.	1.4	10
2	Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103846.	0.9	3
3	MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2022, 439, 120320.	0.3	5
4	Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 189-194.	0.9	25
5	The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 3316-3324.	1.8	6
6	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	5.8	219
7	Fatigue, insomnia and daytime sleepiness in multiple sclerosis versus narcolepsy. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 566-575.	1.0	7
8	Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of life. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102977.	0.9	2
9	Follow-up after infectious mononucleosis in search of serological similarities with presymptomatic multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103288.	0.9	8
10	Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world investigation. <i>Journal of Neurochemistry</i> , 2021, 159, 618-628.	2.1	26
11	NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102463.	0.9	20
12	Intrathecal immunoreactivity in people with or without previous infectious mononucleosis. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 161-168.	1.0	2
13	Can multiple sclerosis be cured? A case of highly active relapsing multiple sclerosis treated with autologous hematopoietic stem-cell transplantation 13 years ago. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102253.	0.9	3
14	Inflammation-related plasma and CSF biomarkers for multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12952-12960.	3.3	102
15	Neuronal antibodies in adult patients with new-onset seizures: A prospective study. <i>Brain and Behavior</i> , 2019, 9, e01442.	1.0	8
16	Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 422-427.	1.0	6
17	Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. <i>Journal of Neuroinflammation</i> , 2019, 16, 16.	3.1	22
18	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455

#	ARTICLE	IF	CITATIONS
19	Leukoencephalopathy, demyelinating peripheral neuropathy and dural ectasia explained by a not formerly described de novo mutation in the SAMD9L gene, ends 27 years of investigations – a case report. <i>BMC Neurology</i> , 2019, 19, 89.	0.8	10
20	Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 147-156.	1.0	15
21	Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 177-183.	1.0	3
22	A SCA7 premutation may be a novel Mendelian modifier of MS course: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, 148-150.	0.9	1
23	Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 1060-1067.	1.7	27
24	Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis. <i>Scientific Reports</i> , 2019, 9, 17309.	1.6	5
25	Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive <sc>MS</sc> from relapsing–remitting <sc>MS</sc>. <i>Journal of Neurochemistry</i> , 2018, 146, 322-332.	2.1	14
26	Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-BarrÉ syndrome: A pilot study. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 143-150.	1.0	24
27	Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. <i>PLoS ONE</i> , 2018, 13, e0194828.	1.1	32
28	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 62-71.	1.4	81
29	Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. <i>Journal of Neuroimmunology</i> , 2017, 306, 25-30.	1.1	17
30	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. <i>Neurology</i> , 2017, 89, 2230-2237.	1.5	307
31	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing–remitting multiple sclerosis. <i>Journal of Neurochemistry</i> , 2017, 141, 296-304.	2.1	124
32	Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society. <i>Acta Neurologica Scandinavica</i> , 2017, 135, 17-24.	1.0	57
33	High Interferon- γ Uniquely in V α 1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2017, 8, 260.	2.2	19
34	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. <i>Annals of Neurology</i> , 2016, 79, 950-958.	2.8	190
35	Rituximab in multiple sclerosis. <i>Neurology</i> , 2016, 87, 2074-2081.	1.5	278
36	Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long–term outcome in patients with autoimmune encephalitis. <i>European Journal of Neurology</i> , 2016, 23, 796-806.	1.7	46

#	ARTICLE	IF	CITATIONS
37	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1587-1595.	1.4	73
38	YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 292, 52-57.	1.1	64
39	Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2015, 358, 201-206.	0.3	22
40	Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 43-50.	1.4	101
41	CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment. <i>Journal of Neuroimmunology</i> , 2014, 269, 87-89.	1.1	51
42	The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013, 264, 100-105.	1.1	30
43	Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 882-888.	1.8	131
44	Cardiovascular regulation in the mudpuppy <i>Necturus maculosus</i> at rest and during short term exercise. <i>Experimental Biology</i> , 1989, 48, 253-9.	0.1	2